Literature DB >> 18693062

Minority enrollment in Parkinson's disease clinical trials.

Myra G Schneider1, Christopher J Swearingen, Lisa M Shulman, Jian Ye, Mona Baumgarten, Barbara C Tilley.   

Abstract

Under-representation of minorities in clinical trials limits access to information relevant to all segments of the population. We assessed the enrollment of minority subjects with Parkinson's disease (PD) into clinical trials. We searched PubMed for published studies of PD trials conducted in the US over the past 20 years and found that only 41 reported racial/ethnic participation (17%). In those trials reporting race/ethnicity, 8% of subjects were non-white, compared to 20% of the non-white US population over age 60. Results of this study identified the need for better reporting of racial composition in clinical trials and for the enrollment of more minority participants in research studies.

Entities:  

Mesh:

Year:  2008        PMID: 18693062      PMCID: PMC2700020          DOI: 10.1016/j.parkreldis.2008.06.005

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  69 in total

1.  A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2000 Jan-Feb       Impact factor: 1.592

2.  TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  C Warren Olanow; Anthony H V Schapira; Peter A LeWitt; Karl Kieburtz; Dirk Sauer; Gianfranco Olivieri; Harald Pohlmann; Jean Hubble
Journal:  Lancet Neurol       Date:  2006-12       Impact factor: 44.182

3.  Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Authors:  Joseph H Friedman; Robert M Berman; Christopher G Goetz; Stewart A Factor; William G Ondo; Joanne Wojcieszek; William H Carson; Ronald N Marcus
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

4.  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.

Authors: 
Journal:  Neurology       Date:  2007-01-02       Impact factor: 9.910

5.  Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

Authors:  J Antonelle deMarcaida; Steven R Schwid; William B White; Karen Blindauer; Stanley Fahn; Karl Kieburtz; Matthew Stern; Ira Shoulson
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

6.  Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life.

Authors:  A M Damiano; M M McGrath; M K Willian; C F Snyder; P A LeWitt; P F Reyes; R R Richter; E D Means
Journal:  Qual Life Res       Date:  2000-02       Impact factor: 4.147

Review 7.  Epidemiology of Parkinson's disease.

Authors:  Lonneke M L de Lau; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

8.  A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Parkinson Study Group.

Authors: 
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

Review 9.  Population issues in clinical trials.

Authors:  Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2007-05

10.  Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.

Authors:  Joseph Jankovic; Ray L Watts; Wayne Martin; Babak Boroojerdi
Journal:  Arch Neurol       Date:  2007-05
View more
  23 in total

1.  Swallowing in patients with Parkinson's disease: a surface electromyography study.

Authors:  Maria das Graças Ws Coriolano; Luciana R Belo; Danielle Carneiro; Amdore G Asano; Paulo José Al Oliveira; Douglas Monteiro da Silva; Otávio G Lins
Journal:  Dysphagia       Date:  2012-05-27       Impact factor: 3.438

Review 2.  Teleneurology and mobile technologies: the future of neurological care.

Authors:  E Ray Dorsey; Alistair M Glidden; Melissa R Holloway; Gretchen L Birbeck; Lee H Schwamm
Journal:  Nat Rev Neurol       Date:  2018-04-06       Impact factor: 42.937

3.  Knowledge and attitudes about Parkinson's disease among a diverse group of older adults.

Authors:  Sarah Pan; Julie Stutzbach; Suzanne Reichwein; Brian K Lee; Nabila Dahodwala
Journal:  J Cross Cult Gerontol       Date:  2014-09

4.  A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy.

Authors:  Barbara C Tilley; Arch G Mainous; Jordan J Elm; Elisabeth Pickelsimer; Lea H Soderstrom; Marvella E Ford; Vanessa A Diaz; Laura A Siminoff; Keith Burau; Daniel W Smith
Journal:  Clin Trials       Date:  2012-04       Impact factor: 2.486

5.  Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Authors:  Jordan J Elm
Journal:  Mov Disord       Date:  2012-10       Impact factor: 10.338

6.  Treatment disparities in Parkinson's disease.

Authors:  Nabila Dahodwala; Ming Xie; Elizabeth Noll; Andrew Siderowf; David S Mandell
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

7.  Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study.

Authors:  Thomas F Tropea; Noor Amari; Noah Han; Jacqueline Rick; EunRan Suh; Rizwan S Akhtar; Nabila Dahodwala; Andres Deik; Pedro Gonzalez-Alegre; Howard Hurtig; Andrew Siderowf; Meredith Spindler; Matthew Stern; Mary Ann Thenganatt; Daniel Weintraub; Allison W Willis; Vivianna Van Deerlin; Alice Chen-Plotkin
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

8.  Hispanic Perspectives on Parkinson's Disease Care and Research Participation.

Authors:  Lisa Damron; Irene Litvan; Ece Bayram; Sarah Berk; Bernadette Siddiqi; Holly Shill
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample.

Authors:  Nabila Dahodwala; Allison W Willis; Pengxiang Li; Jalpa A Doshi
Journal:  Mov Disord Clin Pract       Date:  2016-08-22

10.  Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial.

Authors:  Barbara C Tilley; Arch G Mainous; Rossybelle P Amorrortu; M Diane McKee; Daniel W Smith; Ruosha Li; Stacia M DeSantis; Sally W Vernon; Gary Koch; Marvella E Ford; Vanessa Diaz; Jennifer Alvidrez
Journal:  Contemp Clin Trials       Date:  2021-07-30       Impact factor: 2.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.